7 April 2020
Quarterly Cashflow and Activity Report
20 March 2020
Appendix 2A
4 March 2020
Okamoto licenses VivaGel® antiviral condom in Asian countries
2 March 2020
Starpharma appoints David McIntyre and Appendix 3X
24 February 2020
Interim Report and Half-Year Financial Results
13 February 2020
VivaGel BV launched in Asia
12 February 2020
David McIntyre appointed as non-executive director
11 February 2020
Starpharma receives US$3M milestone from AstraZeneca
30 January 2020
Shareholder Update January 2020
29 January 2020
Quarterly Cashflow Report
24 January 2020
Appendix 3B
30 December 2019
Commencement of phase 1 trial for AZD0466 utilising DEP®
16 December 2019
Starpharma receives $4.9M R&D tax incentive refund
10 December 2019
DEP® cabazitaxel progresses to phase 2 on positive results
4 December 2019
Appendix 3B
4 December 2019
Change in Director's Interest Notice - J Fairley
21 November 2019
AGM Results
21 November 2019
AGM Chairman’s address and CEO’s presentation
20 November 2019
VivaGel® condom receives regulatory approval in Europe
19 November 2019
2019 AGM details

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.